Business ❯ Pharmaceuticals

Investment

Manufacturing Job Creation Research and Development AstraZeneca International Business U.S. Operations Healthcare Industry Life Sciences Economic Impact Economic Development Trade Healthcare Sector Multinational Companies Corporate Strategy Corporate Decisions Private Equity Expansion Plans Foreign Direct Investment Contract Manufacturing International Relations Biotechnology US Market Market Expansion Capacity Expansion Production Facilities International Expansion Weight Loss Medications Global Markets International Investment International Operations International Competitiveness Public Investment Government Funding Dublin Development Clinical Trials

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

The lead asset SYH2082 is progressing into Phase 1 following the signing.

AstraZeneca Pledges $15 Billion China Expansion Through 2030

GSK Pledges $30 Billion U.S. Investment as UK Drug-Pricing Standoff Drives Pullbacks

AstraZeneca Pauses £200m Cambridge Plan as Merck Axes £1bn London Hub

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030